Are you Dr. Dees?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 107 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
101 Manning Dr
Chapel Hill, NC 27599Phone+1 919-966-4996Fax+1 919-843-5515- Is this information wrong?
Summary
- Dr. Elizabeth Dees, MD is an oncologist in Chapel Hill, North Carolina. She is currently licensed to practice medicine in North Carolina and Maryland. She is affiliated with University of North Carolina Hospitals and is an Associate Professor of Hematology & Oncology at University of North Carolina School of Medicine.
Education & Training
- Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1996 - 1999
- Brigham and Women's HospitalResidency, Internal Medicine, 1993 - 1996
- Duke University School of MedicineClass of 1993
Certifications & Licensure
- NC State Medical License 1999 - 2024
- MD State Medical License 1996 - 2000
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- Top MD Consumers Checkbook
Clinical Trials
- S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer. Start of enrollment: 2005 Jul 01
- Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer Start of enrollment: 2001 May 01
- Vinflunine and Erlotinib or Pemetrexed in Treating Patients With Unresectable or Metastatic Solid Tumors Start of enrollment: 2006 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- 2 citationsA phase II single-arm trial of memantine for prevention of cognitive decline during chemotherapy in patients with early breast cancer: Feasibility, tolerability, accep...Zev M Nakamura, Allison M Deal, Eliza M Park, Kate E Stanton, Yesy E Lopez, Laura J Quillen, Erin O'Hare Kelly, Hillary M Heiling, Kirsten A Nyrop, Emily M Ray, E Clai...> ;Cancer Medicine. 2023 Apr 1
- 5 citationsA randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013.Foluso O Ademuyiwa, Feng Gao, Cherease R Street, Ina Chen, Donald W Northfelt, Robert Wesolowski, Mili Arora, Adam Brufsky, E Claire Dees, Cesar A Santa-Maria, Roisin ...> ;NPJ Breast Cancer. 2022 Dec 30
- 7 citationsClinical subtype, treatment response, and survival in De Novo and recurrent metastatic breast cancer.Danielle M File, Tomas Pascual, Allison M Deal, Amy Wheless, Charles M Perou, E Claire Dees, Lisa A Carey> ;Breast Cancer Research and Treatment. 2022 Nov 1
- Join now to see all
Grant Support
- Clinical Trial: Lccc 0509: A Two-Arm Phase I Dose Escalation Trial Of VinflunineNational Center For Research Resources2008
- MLN8054, Aurora A Kinase Inhibitor In Patients With Advanced Solid TumorNational Center For Research Resources2007
- Lccc 0509: A Two-Arm Phase I Dose Escalation Trial Of VinflunineNational Center For Research Resources2007
- Calgb 60301: Sorafenib For Solid Tumors And Ham MalignanciesNational Center For Research Resources2006–2007
- Phase I Radiosensitization Study Of GW572016 In Recurrent Breast CancerNational Cancer Institute2006–2007
- Combination Of Pegylated Liposomal Doxil With PS-341 In Patients With MalignancNational Center For Research Resources2005–2007
- P450 Phenotype And Chemotherapy Toxicity In The ElderlyNational Center For Research Resources2002–2006
- Relationship Between Paclitaxel Pharmacokinetics And Phenotypic MarkersNational Center For Research Resources2004
- NSABP P-1: Trial To Determine Worth Of Tamoxifen For Preventing Breast Cancer.National Center For Research Resources2004
Professional Memberships
- Member
Hospital Affiliations
- University of North Carolina HospitalsChapel Hill, North Carolina